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ABSTRACT von Willebrand factor (vWF) is essential for
the induction of occlusive thrombosis in stenosed and injured
pig arteries and for normal hemostasis. To separate the
relative contribution of plasma and platelet vWF to arterial
thrombosis, we produced chimeric normal and von Wille-
brand disease pigs by crossed bone marrow transplantation;
von WilHebrand disease (vWD) pigs were engrafted with normal
pig bone marrow and normal pigs were engrafted with vWD
bone marrow. Thrombosis developed in the chimeric normal
pigs that showed normal levels of plasma vWF and an absence
of platelet vWF; but no thrombosis occurred in the chimeric
vWD pigs that demonstrated normal platelet vWF and an
absence ofplasma vWF. The ear bleeding times ofthe chimeric
pigs were partially corrected by endogenous plasma vWF but
not by platelet vWF. Our animal model demonstrated that
vWF in the plasma compartment is essential for the develop-
ment of arterial thrombosis and that it also contributes to the
maintenance of bleeding time and hemostasis.
von Willebrand factor (vWF) is a large adhesive glycoprotein that
is synthesized in the endothelial cells (1, 2) and megakaryocytes
(3, 4) and present in platelet a granules (3, 5-7). Plasma vWF
carries factor VIII (F.VIII) (8), prolongs its half-life (9-11),
protects it from degradation by activated protein C (12, 13),
functions as a cofactor in thrombin-dependent cleavage of the
F.VIII light chain (14), and modulates the activation of F.VIII and
factor X (15, 16). The absence ofvWF produces von Willebrand
disease (vWD), an inherited and sometimes fatal bleeding dis-
order. vWF supports platelet adhesion to vascular subendothe-
lium at high shear rates (17) and supports spreading of adherent
platelets in vivo in pigs (18, 19) and in ex vivo models of platelet
adhesion (20-22). In addition, vWF supports the development of
occlusive arterial thrombosis in stenosed and injured arteries in
animal models (23-26). What remains incompletely understood
is how the vWF in the individual plasma and platelet compart-
ments supports these diverse processes in thrombosis and hemo-
stasis.
The role of plasma and platelet vWF in hemostasis relates
in part to the compartmentalization or cellular source ofvWF,
and it also varies among species. Studies in humans and pigs
demonstrate that bleeding time prolongation is associated with
decreased platelet vWF, independent of changes in plasma
vWF (5, 27-30). Interestingly, for porcine vWD and human
type III vWD, infusion of plasma and platelet vWF is required
to normalize the bleeding time, whereas infusion of plasma
vWF alone is insufficient (5, 31-34). In contrast, infusion of
F.VIII-deficient canine cryoprecipitate largely corrects the
bleeding time in canine vWD (26). Moreover, normal dogs
lacking platelet vWF but possessing normal plasma and en-
dothelial vWF exhibit normal bleeding times (26). Bleeding
time correction thus requires infusion of plasma and platelet
vWF in pigs and humans with vWD; but in normal and vWD
dogs, plasma vWF alone is sufficient.
Normal and vWD pigs make excellent models for the study
of the relative contribution of plasma and platelet vWF to
arterial thrombosis, especially since vWF has proven critical
for induction of thrombosis in pigs (23-25). Pigs with vWD are
the oldest known animal model of a human bleeding diathesis
(35-38). These pigs have an autosomally inherited bleeding
disease (39) that is similar to human type IIIvWD (40, 41). We
chose bone marrow transplantation as a method for producing
chimeric animals whose vWF is restricted to either plasma or
platelets. Transplantation of the wild-type porcine vWF or
vWD gene in previous studies altered the expression of vWF
in the plasma and platelets of recipient pigs (5, 29, 42). The
purpose of producing these animals was to determine the
individual contribution of vWF in the plasma or platelet
compartments to thrombosis and hemostasis (43). In this
paper, the plasma vWF compartment in the transplanted pigs
also includes the endothelial and subendothelial compart-
ments (2, 44, 45). The results show that vWF can be isolated
in these two compartments by bone marrow transplantation
between normal and vWD pigs, that plasma vWF in the
absence of platelet vWF supports thrombosis and partially
corrects bleeding time, and that platelet vWF by itself cannot
support thrombosis or bleeding time.
MATERIALS AND METHODS
Experimental Animals. Normal (n = 10) and vWD (n = 10)
pigs came from the colony at the Institut National de la Re-
cherche Agronomique, Jouy-en-Josas, France (Fig. 1). This
colony ofvWD pigs was established by a gift of E. J. W. Bowie,
(Rochester, MN). Eight normal and eight vWD pigs were used
for donor and recipient pigs in bone marrow transplantation
Abbreviations: F.VIII, factor VIII; vWD, von Willebrand disease;
vWF, von Willebrand factor; Ag, antigen; SBT, saline bleeding time;
TEM, transmission electron microscopy.
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FiG. 1. Crossed bone marrow transplantation between normal and
vWD disease pigs to produce chimeras. Twelve pigs were used in our
study (six vWD and six normal). Eight chimeric pigs were produced.
Four pigs (two vWD and 2 normal) were used as nontransplanted
controls.
studies (Fig. 1). Two normal and two vWD pigs served as
nontransplanted controls in our studies.
Plasma and Platelet vWF and F.VIII Assays. Platelet-poor
plasma, platelet rich plasma, washed platelets, and platelet
lysates were prepared and analyzed for vWF activity as de-
scribed (19, 26, 39). vWFR antigen (vWF.Ag) multimers were
separated and analyzed (26, 46). vWF-Ag was assayed by
ELISA (2, 7). F.VIII coagulant activity was performed by a
modified one-stage method (26, 47). One unit of either vWF
or F.VIII activity equaled the amount present in 1 ml of normal
pig pooled plasma.
Bleeding Time. Saline ear bleeding times were performed on
all pigs (36).
Bone Marrow Transplantation in Pigs. Two phenotypic
variants of pigs were produced using a strategy of cross bone
marrow transplantation (Fig. 1): (i) Chimeric vWD pigs with
platelet vWF. Briefly, vWD pigs (n = 4) were irradiated to kill
native bone marrow cells and then transplanted with bone
marrow from a swine leukocyte Ag-matched normal pig
(48-50). Bone marrow recovery in these pigs will be described
elsewhere (unpublished data by one of the coauthors, J.R.). No
pig received immunosuppressive therapy, and the transplanted
pigs were subjected to thrombosis studies described below
within 2 months of transplantation. (ii) Chimeric normal pigs
with no platelet vWF. Normal pigs (n = 4) were irradiated and
then transplanted with bone marrow from avWD pig matched
immunologically in an identical fashion to the chimeric vWD
pigs.
Chromosome Analysis. All transplanted pigs received mar-
row from a pig of the opposite sex. Successful engraftment of
all chimeras was documented by identifying the karyotype of
the donor's sex in cultured bone marrow cells (51).
Arterial Stenosis and Injury Procedure: Animal Prepara-
tion, Histological Studies, and Vessel Morphometry. The
carotid and coronary arterial stenosis and injury procedure
was performed using a modified procedure of Folts and
Uchida (23-26, 52-54). Arteries were pressure-perfused and
placed in fixatives. The degree of arterial stenosis and injury
was measured by computer-assisted planimetry, and the pres-
ence or absence of thrombosis was determined by examining
arterial sections with light microscopy (23-26). Coronary and
carotid artery results were grouped for analysis since we
previously found equivalent incidences of thrombosis in the
two circulations relative to the presence or absence ofvWF (23,
24), and in this study, all pigs demonstrated the same outcome
for their carotid and coronary arteries.
Infusion of vWF. Porcine vWF devoid of porcine F.VIII
(Porton Speywood, Ltd., Birmingham, England) was infused
over 30 min. F.VIII activity, vWF activity, Ag, and multimeric
distribution were determined for each infusate and for plasma
samples collected every 30 min during the stenosis and injury
procedure.
Evaluation of Release of vWF by Adherent Platelets in
Baumgartner Annular Perfusion Systems. Platelets circulat-
ing in the chimeric vWD pigs were evaluated for their ability
to adhere to exposed subendothelium and release of vWF at
a shear rate of 1700 sec-1 (24). The Baumgartner system was
constructed to contain (i) an artery from avWD pig and whole
blood from a chimeric vWD pig expressing normal platelet
vWF, (ii) an artery from a vWD pig and whole blood from a
wild-type vWD pig expressing neither platelet nor plasma
vWF, and (iii) a normal porcine artery and normal pig blood.
The perfused arterial segments were evaluated for vWF de-
position from platelets by an immunogold labeling procedure
(55).
Statistical Methods of Analysis. All measured variables are
reported individually and as mean values for groups. The
Wilcoxon rank sum test was used to compare the two trans-
planted pig groups for variables with ordinal or interval levels
of measurement. Unless otherwise noted, P values are from
these tests. Fisher's exact test was used for comparisons
concerning dichotomous variables.
RESULTS
Characterization of Chimeric Normal Pigs. The strategy of
transplanting vWD bone marrow into normal pigs was utilized
to produce chimeras that expressed normal plasmavWF but no
platelet vWF (Fig. 1). Plasma from these chimeric normal pigs
had normal vWF Ag and activity and a full range of multimers
(Table 1; Fig. 2). The platelet lysates from these pigs had no
vWF activity or Ag and no vWF multimers (Table 1; Fig. 2).
The function of isolated plasma vWF in the absence of platelet
vWF was then tested in these chimeric normal pigs. First,
arterial thrombosis in response to stenosis and injury devel-
oped in six of six arteries (Table 1, three of three coronary,
three of three carotid). By comparison, four of four arteries
(two of two coronary, two of two carotid) tested in two normal
control pigs developed thrombosis with stenosis and injury.
Second, the saline bleeding time (SBT) exhibited a range from
1 2 3 4 5
FIG. 2. Multimeric distribution of vWF-Ag in the plasma and
platelets in chimeric normal and vWD pigs following bone marrow
transplantation. Lanes 1 and 2, platelet lysates and plasma samples,
respectively, from pig no. 95080, a normal pig grafted with vWD pig
bone marrow. Lanes 3 and 4, platelet lysate and plasma samples,
respectively, from pig no. 95136, a vWD pig grafted with normal pig
marrow. Lane 5, normal pig pooled plasma for comparison. The range
of multimers in the compartments with vWF is equivalent to that seen
in normal pig pool plasma.
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Table 1. Characterization of normal pigs: Chimeric and wild type
Normal




Multimers Absent Full range
Plasma vWF*
Ag 163.8 ± 120.2 180
Activity 91.3 ± 9.8 165
Multimers Full range Full range
Thrombosist 6/6 4/4
Bleeding time (min) 6.1 ± 2.2 3.8 ± 1.5
F.VIII* 97.3 ± 2.5 123
Platelet count (per ,ul) 391,000 ± 63,100 438,000
*vWF activity, vWF Ag, and F.VIII are expressed as a % of normal pig
plasma pool. The values listed for the transplant recipients were
determined using samples taken at the time of the terminal experi-
ment, which was at least 2 weeks after receiving any blood products.
The values listed for the two vWD control pigs are the average of the
two individual values. Distributions of hematocrits were similar
among groups in Tables 1 and 2 (data not shown).
tND, not done. The average platelet vWF-Ag in normal pigs at
Jouy-en-Josas is 238 ± 113 (n = 10).
4These values indicate the number of stenosed and injured arteries that
developed thrombosis per total number of arteries tested. The degree
of stenoses induced by the Goldblatt clamp and injury varied over a
large range in all phenotypes, for wild-type normal andvWD pigs and
for both groups of chimeric pigs (data not shown).
3.5 min to 8.5 min in these chimeric normal pigs (mean, 6.8 ±
2.2, Table 1). The average SBT in wild-type normal pigs is 3.8
+ 1.5 min. Finally, F.VIII activity was unchanged in the
absence of platelet vWF (Table 1). Thus, plasma vWF by itself
supports thrombosis, helps correct bleeding time, and contrib-
utes to normal F.VIII activity.
Characterization ofChimeric vWD Pigs. We grafted normal
bone marrow into vWD pigs to produce chimeric vWD pigs
that had normal bone marrow and thus expressed platelet vWF
but no plasma vWF (Fig. 1). Platelet lysates from chimeric
vWD animals expressing normal platelet vWF had mean vWF
Ag and activity values of 211% and 110%, respectively (Table
2). Also, a full range ofvWF multimers was detected in platelet
lysates (Fig. 2). Plasma from the chimeric vWD pigs grafted
with normal bone marrow had <1% vWF Ag and <1% vWF
activity following transplantation (Table 2). There were no
detectable plasma vWF Ag multimers in this group following
transplantation (Fig. 2). The function of isolated platelet vWF
in the absence of plasma vWF was then tested in these chimeric
normal pigs. First, arterial thrombosis in response to stenosis
and injury developed in none of the seven arteries of the
Table 2. Characterization of vWD pigs: Chimeric and wild type
vWD
Parameter Chimeric (n = 4) Wild type (n = 4)
Platelet vWF
Ag 211 ± 133.6 <1
Activity 110 ± 56.1 <1






Bleeding time (min) >15 >15
F.VIII 7.2 ± 5.9 8
Platelet count (per LI) 391,000 ± 63,100 498,000
Values are listed in an identical fashion to those in Table 1.
chimeric vWD pigs (Table 2, zero of three coronary arteries,
zero of four carotid arteries). The difference between the
incidence of thrombosis between chimeric vWD and chimeric
normal pigs is significant (one-sided P = 0.029 for percentage
of tested arteries with thrombosis per pig, Fisher's exact test;
and two-sided P < 0.01 for tested arteries in their own right,
Fisher's exact test). Second, the SBT was >15 min (Table 2).
Finally, F.VIII activity was depressed to a level equal to that
found in vWD control pigs (Table 2). Thus, platelet vWF by
itself does not support thrombosis, correct bleeding time, or
contribute to normal F.VIII activity.
Platelet Function in Chimeras. The function of platelets pro-
duced by transplanted megakaryocytes in the chimeric pigs was
investigated in a Baumgartner annular perfusion chamber. Plate-
lets from chimeric vWD pigs with normal platelet vWF were
shown to adhere to vascular subendothelium in an annular per-
fusion chamber by transmission electron microscopy (TEM)
(Fig. 3A). These platelets revealed immunogold deposition in
granules and on their surface in a pattern that was identical to
normal platelets adherent to normal pig arterial subendothe-
lium (Fig. 3B). By comparison, adherent platelets from a
chimeric normal pig transplanted with vWD marrow revealed
no immunogold deposition in granules or on the membrane
surface (Fig. 3 C). Thus, platelets produced by transplanted
megakaryocytes in the vWD chimeras were capable of attach-
ing to vascular subendothelium and releasing vWF.
Effect of Infusion of F.VIII-Free Porcine vWF into Chimeric
vWD Pigs on Hemostasis and Thrombogenesis. Porcine vWF
was infused into chimeric vWD pigs expressing platelet vWF to
investigate the possibility of an interaction between the vWF
in the two compartments on bleeding time and thrombosis
(Table 3). In these three chimeric vWD pigs, plasma vWF
activity and Ag increased and a full range of multimers of
vWF-Ag was detected in the infusate and in the plasma
following infusion (Table 3). The distribution of high molec-
ular weight multimers was comparable by laser densitometry
to that present in normal pig pool plasma (data not shown).
Despite the presence of vWF functionally and antigenically in
the plasma and platelets, the SBT remained >15 min in all
three pigs and none of the six arteries developed evidence of
thrombosis following stenosis and injury (Table 3). There was
<1% F.VIII activity in all three samples of the porcine vWF
infusion product. Mean F.VIII levels in the pigs rose only
slightly in the infused animals, from 7.2% to 22% with
monitoring for up to 2 hr. The infused porcine vWF product
did not correct bleeding time or support thrombosis in these
chimeras.
DISCUSSION
The purpose of this study was to produce pigs with vWF
isolated to the plasma or platelet compartments and to deter-
mine the contribution of vWF in these individual compart-
ments to thrombosis and hemostasis. The strategy of crossed
bone marrow transplantation between normal and vWD pigs
was chosen to produce chimeric vWD and normal pigs with
and without platelet vWF, respectively. Analysis of plasma and
platelets from these chimeric pigs confirmed that the crossed
bone-marrow transplantation strategy was successful at mod-
ulating platelet vWF expression in vivo. Chimeric normal pigs
expressed no platelet vWF, readily developed thrombosis, and
exhibited partially corrected bleeding times. Conversely, chi-
meric vWD pigs expressed normal platelet vWF that was
releasable at sites of exposed subendothelium but was not able
to support thrombosis or correct prolonged bleeding times.
Thus, vWF in the plasma compartment, endogenously pro-
duced, is essential for supporting thrombosis and, to a large
extent, for correcting prolonged bleeding time.
It is interesting to note that vWD pigs with normal platelet
vWF did not develop thrombosis or exhibit shortened bleeding
Medical Sciences: Nichols et at





FIG. 3. Immunogold labeling of platelet vWF reveals the presence
(arrowheads) or absence of specific antibody binding in platelet granules
and on the surface of the adherent platelets. (A) TEM of normal platelets
in a chimeric vWD pig. (X22,500.) Platelets are adhering to a vWD
arterial subendothelium that had been perfused with blood from the
transplanted pig in an annular perfusion chamber. Labeling of the platelet
surface and granular material on platelets has been attributed to mul-
timers of vWF (56, 57). (B) TEM of normal platelets has been attributed
to multimers of vWF (56, 57). (B) TEM of normal platelets in a normal
pig. (X21,700.) Platelets are adhering to a normal pig arterial subendo-
thelium that had been perfused with normal pig blood in an annular
perfusion chamber. (C) TEM ofvWD platelets from a chimeric normal
pig. (X23,550.) The vWD platelets are adhering to normal pig subendo-
thelium that had been perfused with blood from the transplanted pig in
an annular perfusion chamber. No immunogold labeling for vWF in the
adherent platelets is detected.
Table 3. Influence of infused plasma vWF on bleeding time and
arterial thrombosis in chimeric vWD pigs expressing normal
platelet vWF
Plasma
vWF vWF vWF Bleeding Thrombosis
Pig infusate, activity, Ag, time, per no. of
no. units/kg % % min arteries*
95136 31.8 72 25 >15 0/2
95149 27.6 30 30 >15 0/2
05087 73.7 175 150 >15 0/2
>15 0/6
*At baseline, none of seven arteries developed thrombosis (Table 2).
When thrombosis did not occur, three of the four pigs were then
infused with porcine vWF and monitored for an additional 60-120
min. In addition, the stenosis and injury protocol was performed on
a separate artery in pig 05087 following vWF infusion. Bleeding time
determinations were repeated at 30-min intervals during the stenosis
and injury experimental procedure (3 hr).
times when infused with porcine vWF. In a series of infusions
studies with vWD pigs (including the present study), we have
achieved a wide range of vWF activity (30-175%), with a
complete range of multimers (23, 26, 34). These plasma
infusates did not support bleeding time or thrombosis. Bowie
et al. (5) also noted a prolonged bleeding time in a vWD pig
transplanted with normal marrow but found shortening of the
bleeding time following vWF infusion. This apparent discrep-
ancy could be due to differences in the infused products. Bowie
et al. gave porcine cryoprecipitate and partially purified por-
cine vWF, while we infused chimeric vWD pigs with a porcine
vWF product that had been concentrated in a process that
separates porcine F.VIII. It is possible that processing plasma
vWF alters the protein in such a way that it is not able to
support thrombosis as does endogenous or native vWF. Al-
ternatively, vWF in the subendothelium may be important for
the correction of bleeding time or for the support of throm-
bosis. Further work is needed to clarify these issues.
The bleeding time was slightly prolonged in the normal pigs
that had no platelet vWF. These data suggest that plasma vWF
is a major determinant of bleeding time but that platelet vWF
may also help correct prolonged bleeding times in pigs. Solberg
et al. (29) found the bleeding time was prolonged in a normal
pig withvWD marrow. This pig had no detectable plateletvWF
by immunofluorescence and plasma vWF ristocetin cofactor
activity of 10-20%. In humans, platelet vWF is also an
important determinant of bleeding time (27, 30-32). In dogs
that do not express platelet vWF, the bleeding time appears to
be largely determined by plasmavWF (26). Thus, there may be
species specificity of platelet vWF function as it relates to
bleeding time. In pigs and humans, however, the vWF in the
two compartments may interact for total correction ofbleeding
time, possibly by local delivery of high concentrations ofvWF
following platelet activation and release.
Bone marrow transplantation between normal and vWD
pigs produced animals that had vWF only in plasma or
platelets. Recent work has identified portions of the human
vWF gene that are responsible for endothelial cell-specific
expression of-vWF (58, 59). To date, no specific regulatory
elements in the human vWF gene have been identified that
drive expression of vWF in megakaryocytes and ultimately
platelet a granules. Since dogs appear to express vWF nor-
mally in their plasma but not in their platelets (26), it is possible
that comparison of regulatory regions of human and pig vWF
genes to the canine vWF gene could elucidate the factors
responsible for platelet expression of vWF.
vWF exhibits complex and diverse roles in thrombosis and
hemostasis. Its function is determined in part by its compart-
mentalization, and it varies among species. Comparative stud-
ies have shown the essential contribution to arterial thrombosis
Proc. Natl. Acad Sci. USA 92 (1995)
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of vWF in the plasma compartments of pigs and dogs and have
also suggested an important role of plasma and platelet vWF
in bleeding time correction or hemostasis in pigs and humans.
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